nav open
¸Þ´º
nav open
ȸ»ç¼Ò°³
Àλ縻(±¹¹®)
Àλ縻(About Us)
¿À½Ã´Â ±æ
»ç¾÷¼Ò°³
»ç¾÷¼Ò°³1
»ç¾÷¼Ò°³2
»ç¾÷ºÐ¾ß
»ç¾÷ºÐ¾ß1
»ç¾÷ºÐ¾ß2
»ç¾÷ºÐ¾ß3
¿Â¶óÀι®ÀÇ
¿Â¶óÀι®ÀÇ(Contact)
Ä¿¹Â´ÏƼ
ÀÚ·á½Ç
nav open
ȸ»ç¼Ò°³
Àλ縻(±¹¹®)
Àλ縻(About Us)
¿À½Ã´Â ±æ
»ç¾÷¼Ò°³
»ç¾÷¼Ò°³1
»ç¾÷¼Ò°³2
»ç¾÷ºÐ¾ß
»ç¾÷ºÐ¾ß1
»ç¾÷ºÐ¾ß2
»ç¾÷ºÐ¾ß3
¿Â¶óÀι®ÀÇ
¿Â¶óÀι®ÀÇ(Contact)
Ä¿¹Â´ÏƼ
ÀÚ·á½Ç
Ä¿¹Â´ÏƼ
¾¾¾ÆÀ̹ÙÀÌ¿À´Â ¹ÏÀ½°ú ½Å·Ú¸¦ ¹ÙÅÁÀ¸·Î
±Í»çÀÇ ±¹³», ÇØ¿ÜÁøÃâÀÇ ÆÄÆ®³Ê°¡ µÇ°Ú½À´Ï´Ù.
Ä¿¹Â´ÏƼ
ÀÚ·á½Ç
Ȩ
Ä¿¹Â´ÏƼ
ÀÚ·á½Ç
ÀÚ·á½Ç
Á¦¸ñ
Preclinical cases to USA ,Reference
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
ÀÛ¼ºÀÏÀÚ
2026-05-07
Á¶È¸¼ö
37
ÀÌ¹Ì ¹Ì±¹ÁøÃâÇÑ Case studyµéÀ»(Oncology°ü·Ã´Ù¼ö) º¸À¯Çϰí ÀÖ½À´Ï´Ù.
(Preformulation service platform)
Preclinical (Medical chemistry, Invivo Phamacology, Toxicology)---Preformulation Accelerate the IND filing of small molecular
drug candidate.
--CMC(Chemistry development, Pharmaceutical development ,Analytical development))
* In vivo pharmacology platform (
Oncology
), For example..
1)Liver cancer: 16 human cancer cell lines
2) Hepa1-6/H22 , mouse cancer cell lines.
* Early pk/efficacy/toxicology formulation development
* Recommedation of Clinical formulation strategy
Other cases will give after CDA, perfectly.
´Ù¾çÇÑ ºÐ¾ß¿¡¼ °¡´ÉÇϸç, ´ë·«ÀûÀ¸·Î´Â
1) Oncology: PDX, PDO & PDC bank. New drug R&D service
2) Non-Oncology: New drug development , Transgenic mice platform
3) Analytics: Biochemical service, Pre-clinical sample analysis, Preformulation service.
4) Lab Animal Capacity:(Numbers opens after CDA,
: 00,000Mice/Rats, 000 Monkeys, 000 Dogs,000 Rabbits, 000 Guinea Pigs)
¹Ì±¹ÁøÃâÀ» Àú·ÅÇÏ°í ºü¸£°ÔÇϽðí,ÀÌÈÄ
IITµîÀ¸·Î Ȱ¿ëÇÏ¿© CMO, Clinical µî ºñ¿ëÀý°¨,TIimeline Àý°¨
ÇϽðí
¿øÇϽô ´Ü°è±îÁö ºü¸£°Ô °¡½Ç¼ö ÀÖ½À´Ï´Ù.
÷ºÎÆÄÀÏ